AKT1 and cancer: Dysregulation correlates with different diseases such as cancer, diabetes, cardiovascular or neurologic malfunctions.1 In cancer, over‐activated upstream mediators, as well as loss of function mutations in the tumor suppressor PTEN but not necessarily mutations in Akt, lead to a constitutive activation of Akt enzymes and make them important targets for therapeutic intervention.2